Bone marrow fibrosis in childhood acute lymphoblastic leukemia correlates to biological factors, treatment response and outcome

Leukemia

Volumn 22, Issue 3, 2008, Pages 504-510

  Noren Nystrom U ^a   Roos, G ^a   Bergh, A ^a   Botling, J ^b   Lonnerholm G ^c   Porwit, A ^d   Heyman, M ^d   Forestier, E ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY CHILDREN S HOSPITAL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

RETICULIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; B LYMPHOCYTE; BONE MARROW BIOPSY; CELL DENSITY; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MYELOFIBROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROLYMPHOCYTE; RETROSPECTIVE STUDY; RISK ASSESSMENT; T LYMPHOCYTE; TREATMENT RESPONSE;

EID: 40749144435     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2405072     Document Type: Article

References (34)

1. Gustafsson G, Schmiegelow K, Forestier E, Clausen N, Glomstein A, Jonmundsson G et al. Improving-outcome through two decades in childhood ALL in the Nordic countries: The impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 2000; 14 2267-2275.
2. Andersson A, Ritz C, Lindgren D, Eden P, Lassen C, Heldrup J et al Microarray-based classification of a consecutive series of 121 childhood acute leukemias: Prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia 2007; 21 1198-1203.
3. Bjorklund E, Mazur J, Soderhall S, Porwit-MacDonald A. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia. Leukemia 2003; 17: 138-148.
4. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96: 2691-2696.
5. Nyvold C, Madsen HO, Ryder LP, Seyfarth J, Svejgaard A, Clausen N et al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 2002; 99: 1253-1258.
6. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352 1731-1738.
7. Gadner H, Haas OA, Masera G, Pui CH, Schrappe M. 'Ponte di Legno' Working Group - report on the Fifth International Childhood Acute Lymphoblastic Leukemia Workshop: Vienna, Austria, 29 April - 1 May 2002. Leukemia 2003; 17: 798-803.
8. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukaemia - current status and future perspectives. Lancet Oncol 2001; 2 597-607.
9. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001; 1: 46-54.
10. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005; 90: 1128-1132.
11. Buesche G, Georgii A, Duensing A, Schmeil A, Schlue J, Kreipe HH. Evaluating the volume ratio of bone marrow affected by fibrosis: A parameter crucial for the prognostic significance of marrow fibrosis in chronic myeloid leukemia. Hum Pathol 2003; 34: 391-401.
12. Kvasnicka HM, Thiele J, Schmitt-Graeff A, Diehl V, Zankovich R, Niederle N et al. Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1+) chronic myelogenous leukemia: A multicenter trial. J Clin Oncol 2001; 19: 2994-3009.
13. Wallis JP, Reid MM. Bone marrow fibrosis in childhood acute lymphoblastic leukaemia. J Clin Pathol 1989; 42: 1253-1254.
14. Thomas X, Le QH, Danaila C, Lheritier V, Ffrench M. Bone marrow biopsy in adult acute lymphoblastic leukemia: Morphological characteristics and contribution to the study of prognostic factors. Leuk Res 2002; 26: 909-918.
15. Narendran A, Ganjavi H, Morson N, Connor A, Barlow JW, Keystone E et al. Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. Exp Hematol 2003; 31: 693-701.
16. Wu S, Korte A, Kebelmann-Betzing C, Gessner R, Henze G, Seeger K. Interaction of bone marrow stromal cells with lymphoblasts and effects of prednisolone on cytokine expression. Leuk Res 2005; 29: 63-72.
17. Campana D, Coustan-Smith E, Manabe A, Kumagai M, Murti KG, Silvennoinen O et al. Human B-cell progenitors and bone marrow microenvironment. Hum Cell 1996; 9: 317-322.
18. Norén-Nyström U, Roos G, Bergh A, Forestier E. Prognostic impact of vascular density and fibrosis in the bone marrow of children with high-risk acute lymphoblastic leukemia. Leukemia 2005; 19: 1998-2001.
19. Bancroft JD, Gamble M. Theory and Practice of Histological Techniques Churchill Livingstone: Edinburgh, 2001.
20. Puff FA. Laidlaw's lithium silver carbonate method to demonstrate reticulin. In: Putt FA (ed). Manual of Histological Staining Methods John Wiley & Sons: New York, 1972, pp 107-109.
21. Weibel E. Stereological methods. In: Stereological Methods Vol 1: Practical Methods for Biological Morphometry. Academic Press: New York, 1979, pp 1-415.
22. Forestier E, Johansson B, Gustafsson G, Borgstrom G, Kerndrup G, Johannsson J, et al. Prognostic impact of karyotypic findings in childhood acute lymphoblastic leukaemia: A Nordic series comparing two treatment periods. For the Nordic Society of Paediatric Haematology and Oncology (NOPHO) Leukaemia Cytogenetic Study Group. Br J Haematol 2000; 110: 147-153.
23. Aziz KA, Till KJ, Zuzel M, Cawley JC. Involvement of CD44-hyaluronan interaction in malignant cell homing and fibronectin synthesis in hairy cell leukemia. Blood 2000; 96: 3161-3167.
24. Kossakowska AE, Edwards DR, Prusinkiewicz C, Zhang MC, Guo D, Urbanski SJ et al. Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Blood 1999; 94 2080-2089.
25. Pegahi R, Poyer F, Legrand E, Cazin L, Vannier JP, Lamacz M. Spontaneous and cytokine-evoked production of matrix metalloproteinases by bone marrow and peripheral blood pre-B cells in childhood acute lymphoblastic leukaemia. Eur Cytokine Netw 2005; 16: 223-232.
26. Sanz-Rodriguez F, Hidalgo A, Teixido J. Chemokine stromal, cell-derived factor-1 alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 2001; 97: 346-351.
27. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997; 150: 815-821.
28. Pule MA, Gullmann C, Dennis D, McMahon C, Jeffers M, Smith OP. Increased angiogenesis in bone marrow of children with acute lymphoblastic leukaemia has no prognostic significance. Br J Haematol 2002; 118: 991-998.
29. Buesche G, Ganser A, Schlegelberger B, von Neuhoff N, Gadzicki D, Hecker H et al. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia. Leukemia 2007; 21: 2420-2427.
30. Pui CH, Boyett JM, Relling MV, Harrison PL, Rivera GK, Behm FG et al Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol 1999; 17: 818-824.
31. Schmiegelow K, Schroder H, Gustafsson G, Kristinsson J, Glomstein A, Salmi T et al. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. J Clin Oncol 1995; 13: 345-351.
32. Shuster JJ, Wacker P, Pullen J, Humbert J, Land VJ, Mahoney Jr DH et al. Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group Study. J Clin Oncol 1998; 16: 2854-2863.
33. Frost BM, Eksborg S, Bjork O, Abrahamsson J, Behrendtz M, Castor A et al. Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: Multi-institutional collaborative study. Med Pediatr Oncol 2002; 38: 329-337.
34. Schmiegelow K, Glomstein A, Kristinsson J, Salmi T, Schroder H, Bjork O. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO). J Pediatr Hematol Oncol 1997; 19: 102-109.